Quoin Pharmaceuticals (QNRX)
NASDAQ:QNRX
Top Page
Quoin Pharmaceuticals
(NASDAQ:QNRX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$7.00
▼(-40.27% Downside)
Action:ReiteratedDate:01/21/26
The score is held down primarily by weak financials (no revenue, sizable losses, and significant cash burn with negative equity), reinforced by bearish technical signals (below key moving averages with negative MACD). Positive corporate catalysts (orphan designation and breakthrough application) provide some offset, but do not outweigh the current funding and execution risks.
Positive Factors
Awareness Campaign Success
The success of the NETHERTON NOW campaign enhances Quoin's visibility and credibility in addressing rare diseases, potentially aiding future product acceptance and partnerships.
Negative Factors
Financial Instability
The lack of revenue and reliance on external financing highlight financial instability, posing risks to operational sustainability and growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Awareness Campaign Success
The success of the NETHERTON NOW campaign enhances Quoin's visibility and credibility in addressing rare diseases, potentially aiding future product acceptance and partnerships.
Read all positive factors
Quoin Pharmaceuticals (QNRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.45M
Dividend YieldN/A
Average Volume (3M)629.04K
Price to Earnings (P/E)―
Beta (1Y)-1.14
Revenue GrowthN/A
EPS Growth-228.89%
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.74
Shares Outstanding838,977
10 Day Avg. Volume1,633,105
30 Day Avg. Volume629,040
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.33
Price to Sales (P/S)0.00
P/FCF Ratio-0.39
Enterprise Value/Market Cap-699.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda272.33
Forecast
1Y Price Target
$40.00Price Target Upside241.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-6.91
Revenue Forecast (FY)N/A
Quoin Pharmaceuticals Business Overview & Revenue Model
Company Description
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops ...
How the Company Makes Money
Quoin Pharmaceuticals generates revenue through the development and commercialization of its pharmaceutical products. The company's revenue model primarily involves the sale of its approved drugs and potential licensing agreements with other pharm...
Quoin Pharmaceuticals Earnings Call Summary
Earnings Call Date:Mar 13, 2024
(Q4-2023)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The earnings call reflects a generally positive outlook for Quoin Pharmaceuticals, with significant progress in clinical trials, strong commercial partnerships, and a solid financial position. However, challenges remain in managing cash burn and executing M&A strategies.Positive Updates
Transformational Year for Quoin
2023 was a transformational year for Quoin, marked by the release of the first-ever clinical data from a trial in Netherton syndrome subjects under an open IND with the FDA. The initial data was positive across several clinical endpoints with no safety signals.
Negative Updates
Net Loss and Cash Burn
Despite a decrease in net loss from $9.4 million in 2022 to $8.7 million in 2023, Quoin still faces financial challenges with ongoing R&D expenses and a net loss of $2 million in Q4 2023.
Read all updates
Q4-2023 Updates
Positive
Negative
Transformational Year for Quoin
2023 was a transformational year for Quoin, marked by the release of the first-ever clinical data from a trial in Netherton syndrome subjects under an open IND with the FDA. The initial data was positive across several clinical endpoints with no safety signals.
Read all positive updates
Company Guidance
During the Q4 2023 earnings call for Quoin Pharmaceuticals (QNRX), key guidance included updates on clinical trials for QRX003, a potential treatment for Netherton syndrome. The company implemented several FDA-cleared protocol amendments, including increasing study size, altering dosing frequency, and lowering eligibility age to 14 years. They have 9 commercial partnerships covering 61 countries and completed a $6.5 million public offering, with an $8 million equity line of credit to extend their cash runway into the second half of 2026. Despite a net loss of $8.7 million for 2023, Quoin remains the only company with an open IND for Netherton syndrome, positioning itself for a pivotal year in 2024.Quoin Pharmaceuticals Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
22
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -14.00M | -9.43M | -9.27M | -8.56M | -20.27M | -1.57M |
| Net Income | -13.77M | -8.96M | -8.69M | -9.38M | -21.46M | -2.10M |
Balance Sheet | ||||||
| Total Assets | 6.42M | 15.71M | 12.17M | 14.46M | 9.36M | 1.38M |
| Cash, Cash Equivalents and Short-Term Investments | 5.41M | 14.06M | 10.69M | 12.85M | 7.48M | 323.83K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.21M |
| Total Liabilities | 7.64M | 6.50M | 6.51M | 7.05M | 8.70M | 7.99M |
| Stockholders Equity | -1.21M | 9.20M | 5.66M | 7.41M | 657.03K | -6.61M |
Cash Flow | ||||||
| Free Cash Flow | -10.74M | -7.86M | -7.86M | -8.73M | -6.35M | -1.46M |
| Operating Cash Flow | -10.74M | -7.86M | -7.86M | -8.48M | -5.72M | -1.34M |
| Investing Cash Flow | 3.81M | -1.89M | 2.19M | -10.15M | -625.00K | -125.00K |
| Financing Cash Flow | 5.64M | 10.97M | 5.22M | 14.01M | 13.50M | 1.79M |
Quoin Pharmaceuticals Technical Analysis
Positive
11.72
Price Trends
8.66
Positive
11.41
Negative
10.13
Negative
Market Momentum
-0.15
Negative
58.69
Neutral
51.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QNRX, the sentiment is Positive. The current price of 11.72 is above the 20-day moving average (MA) of 8.37, above the 50-day MA of 8.66, and above the 200-day MA of 10.13, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 58.69 is Neutral, neither overbought nor oversold. The STOCH value of 51.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QNRX.
Quoin Pharmaceuticals Risk Analysis
Quoin Pharmaceuticals disclosed 54 risk factors in its most recent earnings report. Quoin Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Quoin Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $1.55M | -0.09 | -710.57% | ― | 12.45% | -544.23% | |
45 Neutral | $2.15M | -0.36 | ― | ― | ― | 87.42% | |
44 Neutral | $5.45M | -0.27 | -334.42% | ― | ― | -228.89% | |
44 Neutral | $3.29M | -1.00 | -46.34% | ― | ― | 70.71% | |
44 Neutral | $2.47M | -0.46 | -155.01% | ― | ― | 78.52% |
* Healthcare Sector Average
QNRX
Quoin Pharmaceuticals
7.57
-2.41
-24.12%
GLMD
Galmed Pharmaceuticals
0.59
-1.09
-65.00%
JAGX
Jaguar Animal Health
0.39
-4.99
-92.71%
ADIL
Adial Pharmaceuticals
1.72
-14.53
-89.42%
ALZN
Alzamend Neuro
1.50
-8.40
-84.85%
CLDI
Calidi Biotherapeutics
0.28
-8.06
-96.63%
Quoin Pharmaceuticals Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Quoin seeks Saudi breakthrough status for Netherton therapy
Positive
Jan 20, 2026
On January 20, 2026, Quoin Pharmaceuticals announced that it had filed an application with the Saudi Food and Drug Authority for Breakthrough Medicine Designation for QRX003, its lead late-stage topical candidate for Netherton Syndrome, a rare and...
Business Operations and Strategy
Quoin Pharmaceuticals Approves New Stock Option Agreements
Neutral
Nov 17, 2025
On November 14, 2025, Quoin Pharmaceuticals‘ Board of Directors approved new award agreements for stock options under the company’s 2025 Equity Incentive Plan. These agreements outline the terms for granting equity awards to directors ...
Business Operations and StrategyProduct-Related Announcements
Quoin Pharmaceuticals Achieves Key Milestone in Rapamycin Delivery
Positive
Nov 12, 2025
On November 11, 2025, Quoin Pharmaceuticals announced the successful achievement of target loading concentrations for its two topical rapamycin delivery technologies. A 4% concentration was achieved in their topical formulation and a 5% concentrat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.